Introduction

Hepatocellular carcinoma (HCC) is found within the first five most common tumors worldwide. Sorafenib is an approved agent in HCC treatment. Sertraline is a selective serotonin reuptake inhibitor. The aim of the study is to investigate the combination of sertraline and sorafenib at hepatocellular cancer cell proliferation and death.

Methods

HepG2 cells were treated with drugs and viability test XTT was performed. Cells were stained with hematoxylin and eosin for histological examination or with anti-Bcl-2 antibody and Hoechst 33258 for immunofluorescence.

Results

Viability results supported dose-dependent antiproliferative effect for both sertraline and sorafenib. Microscopic evaluation of stained cells exerts morphological changes.

Discussion

This is the first study to show that sorafenib and sertraline have synergistic effect in hepatocellular cancer.

中文翻译：

---

舍曲林联合索拉非尼：一种针对抑郁症和肝细胞癌的有前景的药物疗法

介绍

肝细胞癌 (HCC) 位于全球前五种最常见的肿瘤中。索拉非尼是经批准的 HCC 治疗药物。舍曲林是一种选择性血清素再摄取抑制剂。该研究的目的是研究舍曲林和索拉非尼的组合对肝细胞癌细胞增殖和死亡的影响。

方法

用药物处理 HepG2 细胞并进行活力测试 XTT。细胞用苏木精和伊红染色用于组织学检查，或用抗 Bcl-2 抗体和 Hoechst 33258 染色用于免疫荧光。

结果

生存力结果支持舍曲林和索拉非尼的剂量依赖性抗增殖作用。染色细胞的显微评估会产生形态变化。

讨论

这是首次表明索拉非尼和舍曲林在肝细胞癌中具有协同作用的研究。